CORRECTED-GTx says muscle drug fails in late-stage trials
(Corrects the number of patients to "about 650" from "about 325")
Aug 19 (Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials.
A 3-mg dose of the drug, enobosarm, was tested on about 650 patients with non-small cell lung cancer - the most common form of lung cancer.
There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss. (Reporting by Pallavi Ail in Bangalore; Editing by Saumyadeb Chakrabarty)
- Atheists face death in 13 countries, global discrimination: study
- Missouri executes man for killing good Samaritan motorist in 1994
- Focus turns to Thai military, anti-government protesters tell them to pick sides |
- Google executives' planes saved millions in costs due to error - NASA
- Apple scores legal victory over Samsung in South Korea